These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 21784585

  • 1. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.
    Cury FL, Duclos M, Aprikian A, Patrocinio H, Kassouf W, Shenouda G, Faria S, David M, Souhami L.
    Int J Radiat Oncol Biol Phys; 2012 Mar 15; 82(4):1417-23. PubMed ID: 21784585
    [Abstract] [Full Text] [Related]

  • 2. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):811-7. PubMed ID: 19836166
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H.
    Int J Radiat Oncol Biol Phys; 2012 Apr 01; 82(5):e795-801. PubMed ID: 22330999
    [Abstract] [Full Text] [Related]

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 5. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.
    Radiother Oncol; 2012 Aug 01; 104(2):181-6. PubMed ID: 22853851
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.
    Int J Radiat Oncol Biol Phys; 2010 Feb 01; 76(2):386-92. PubMed ID: 19427741
    [Abstract] [Full Text] [Related]

  • 7. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N, Faria S, Cury F, David M, Duclos M, Shenouda G, Ruo R, Souhami L.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):534-9. PubMed ID: 23597418
    [Abstract] [Full Text] [Related]

  • 8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 9. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 10. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.
    J Urol; 2005 Sep 01; 174(3):882-7. PubMed ID: 16093980
    [Abstract] [Full Text] [Related]

  • 11. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
    Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC.
    Int J Radiat Oncol Biol Phys; 2013 Jun 01; 86(2):324-9. PubMed ID: 23474112
    [Abstract] [Full Text] [Related]

  • 12. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 01; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 13. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
    Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, Angermeier K, Campbell S, Stephenson A, Klein EA, Wilkinson DA, Ciezki JP.
    Int J Radiat Oncol Biol Phys; 2015 Jul 15; 92(4):884-93. PubMed ID: 25962627
    [Abstract] [Full Text] [Related]

  • 15. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
    Jo Y, Hiratsuka J, Fujii T, Takenaka A, Fujisawa M.
    Urology; 2004 Sep 15; 64(3):556-60. PubMed ID: 15351592
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK, Adams MT, Motta J.
    Brachytherapy; 2008 Sep 15; 7(1):17-21. PubMed ID: 18201939
    [Abstract] [Full Text] [Related]

  • 18. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.
    Int J Radiat Oncol Biol Phys; 2009 Nov 01; 75(3):656-63. PubMed ID: 19250768
    [Abstract] [Full Text] [Related]

  • 19. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
    Martínez-Monge R, Moreno M, Ciérvide R, Cambeiro M, Pérez-Gracia JL, Gil-Bazo I, Gaztañaga M, Arbea L, Pascual I, Aristu J.
    Int J Radiat Oncol Biol Phys; 2012 Mar 01; 82(3):e469-76. PubMed ID: 22284039
    [Abstract] [Full Text] [Related]

  • 20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 01; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.